Takeda Pharmaceutical Company Limited
TAK · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $6,827 | $6,966 | $7,053 | $6,603 |
| - Cash | $681 | $350 | $385 | $494 |
| + Debt | $4,645 | $4,506 | $4,515 | $4,840 |
| Enterprise Value | $10,791 | $11,122 | $11,183 | $10,949 |
| Revenue | $1,113 | $1,107 | $1,053 | $1,144 |
| % Growth | 0.6% | 5.1% | -7.9% | – |
| Gross Profit | $733 | $722 | $671 | $727 |
| % Margin | 65.8% | 65.2% | 63.7% | 63.6% |
| EBITDA | $316 | $439 | $181 | $193 |
| % Margin | 28.4% | 39.7% | 17.2% | 16.9% |
| Net Income | -$12 | $124 | -$103 | $24 |
| % Margin | -1.1% | 11.2% | -9.8% | 2.1% |
| EPS Diluted | -3.74 | 39.12 | -32.62 | 7.51 |
| % Growth | -109.6% | 219.9% | -534.4% | – |
| Operating Cash Flow | $378 | $215 | $222 | $384 |
| Capital Expenditures | -$53 | -$75 | -$49 | -$45 |
| Free Cash Flow | $325 | $140 | $173 | $339 |